.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin led to boosted progression-free as well as total survival, causing FDA commendation and a brand new treatment possibility for patients.